菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics Granted ISO 22301 Certification and Upgraded ISO/IEC 27001 with Expanded Scope
Mar. 31, 2025
WuXi Biologics Granted ISO 22301 Certification and Upgraded ISO/IEC 27001 with Expanded Scope
  • Further strengthening the company’s business continuity management and information security capabilities
  • Building an agile organization and enhancing sustainable development to deliver exceptional solutions for global clients

 

Shanghai, March 31, 2025 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully achieved ISO 22301:2019 Business Continuity Management System (BCMS) certification, and completed a version upgrade and recertification of its ISO/IEC 27001:2022 Information Security Management System (ISMS). These certifications underscore the company’s commitment to excellence in strengthening operational resilience and fortifying information security, while demonstrating its dedication to enhancing risk management capabilities, and providing world-class solutions to clients globally.

 

ISO 22301 is an internationally recognized standard for BCMS. It offers a structured framework to help organizations identify critical business activities and resources, evaluate potential risks, develop effective response strategies, and maintain operations and ensure service delivery, even in unforeseen circumstances. By adopting and optimizing its BCMS in alignment with this standard, WuXi Biologics has further heightened its ability to safeguard operations, protect stakeholder interests, and deliver continuous, uninterrupted services.

 

ISO/IEC 27001 is the global gold standard for ISMS. The certification framework is designed to systematically strengthen information security practices across all levels of an organization, fostering greater awareness and ensuring the protection of critical information assets that support core business functions. WuXi Biologics received this certification for the first time in 2022 and has since broadened its scope. The recent version upgrade and the extension of its certification scope underscore the company’s steadfast commitment to ensuring data security and regulatory compliance.

 

Dr. Chris Chen, CEO of WuXi Biologics, commented, “The achievement of both ISO 22301 and ISO/IEC 27001 certification demonstrates our ability to transform risk management capabilities into agile delivery advantages, providing end-to-end assurance for global partners. As a leader in the CRDMO industry, we have instituted a comprehensive and systematic approach to risk management, strengthened our information security measures, and continuously optimize our global service network. These internationally recognized certifications reflect our commitment to enhancing our responsiveness, adhering strictly to quality standards, and empowering the advancement of innovative therapies through our reliable CRDMO platform.”

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

 

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

 

Contacts

 

Business

info@wuxibiologics.com

 

Media

PR@wuxibiologics.com